Background—Underlying mechanisms in heart failure (HF) with preserved ejection fraction
remain unknown. We investigated cardiovascular plasma biomarkers in HF with preserved …

Background: A systemic proinflammatory state has been hypothesized to mediate the
association between comorbidities and abnormal cardiac structure/function in heart failure …

Heart failure (HF) is multifactorial syndrome with high cardiovascular (CV) morbidity and
mortality rates associated with an increasing prevalence worldwide. Measuring plasma …

Background Underlying inflammation has been increasingly recognized in heart failure with
a preserved ejection fraction (HF p EF). In this study we tested the hypothesis that pro …

Background Biomarkers may help us to unravel differences in the underlying
pathophysiology between heart failure (HF) patients with a reduced ejection fraction (HF r …

Aims Chronic heart failure (HF) is a common disease and one of the leading causes of death
worldwide. Heart failure with preserved ejection fraction (HFpEF) and with reduced ejection …

Aims The lack of effective therapies for patients with heart failure with preserved ejection
fraction (HFpEF) is often ascribed to the heterogeneity of patients with HFpEF. We aimed to …

Many patients with symptoms and signs of heart failure have a left ventricular ejection
fraction≥ 50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a …

Heart failure (HF) is characterized by the elaboration of a portfolio of pro-inflammatory
cytokines and inflammatory mediators that are considered to contribute to disease …

Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for
cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) …